Duloxetine Capsule, Delayed Release
Product Images NDC 60760-759

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-759). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

6076-759 (Duloxetine 60760 759 30)

This is a medication label for duloxetine delayed-release capsules in 20mg strength. The package contains 30 capsules with NDC number 60760-759-30. The manufacturer is Ajanta Pharma USA Inc. The medication is used as directed and should be stored at controlled room temperature between 15°-30°C (59°-86°F).*

FDA Label Image

Figure1 (Duloxetine Fig1)

This text provides information related to a medical study or trial comparing the treatment outcomes of a placebo group versus a group treated with duloxetine in relation to the time from randomization to relapse in patients. The graph appears to show data points at 100, 150, 200, and 250 days, focusing on the number of patients with relapse under each treatment condition.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This text mentions the use of Duloxetine in doses of 60/120 mg once daily as well as details regarding improvement in pain percentage from the baseline. The text also refers to a placebo but does not provide additional details beyond that.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This is a graph showing the proportion of patients with relapse over time for two treatments - placebo and duloxetine. The x-axis represents the time from randomization to relapse in days, while the y-axis shows the proportion of patients. The graph indicates that duloxetine may be associated with a lower rate of relapse compared to placebo over the observed time period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

This text provides information on the percentage of patients improved with different doses of Duloxetine as well as with Placebo. It shows the percentage improvement in pain from the baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo.*

FDA Label Image

Figure4 (Duloxetine Fig4)

This text provides information on the percentage of patients improved with different treatments in terms of pain relief. It specifically compares the effectiveness of Duloxetine 60 mg BID and Duloxetine 60 mg QD with a placebo in improving pain from baseline.*

FDA Label Image

Figure5 (Duloxetine Fig5)

Percentage of Patients Improved: 100 Comparison between Duloxetine 60mg Twice Daily and Duloxetine 60mg Once Daily, as well as the Placebo. Percent Improvement in Pain from Baseline.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

This data shows the percentage of patients who experienced improvement in pain levels when treated with Duloxetine 60 mg once daily compared to placebo. The chart displays a range of improvement percentages from 0 to 100, with specific values highlighted at 80%, 90%, and various increments between 10% and 70%.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This text provides information about the use of Duloxetine at doses of 60 or 120 mg once daily in a study related to Placebo. The text also mentions a percentage improvement in pain from baseline (BOCF).*

FDA Label Image

Figure9 (Duloxetine Fig9)

This description appears to be related to a comparison between placebo and Duloxetine 60 mg once daily in terms of pain improvement from baseline. The text seems to provide data on percentage improvement in pain from baseline for the two treatments. The document may be discussing the effectiveness of Duloxetine in pain management compared to a placebo.*

FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.